Pharmacovigilance & Post-Market Compliance
Future trends in REMS simplification and digital enablement
Future Trends in REMS Simplification and Digital Enablement Risk Evaluation and Mitigation Strategies (REMS) have become an essential component of the U.S. Food and Drug Administration’s (FDA) approach to ensuring that the benefits of certain drugs outweigh their risks. As pharmaceutical innovation accelerates, the complexities surrounding the post-marketing commitments (PMCs) tied to REMS programs are evolving. This comprehensive guide discusses future trends in REMS simplification and digital enablement, catering to professionals in clinical operations, regulatory affairs, and medical affairs in the U.S., U.K., and EU markets. Understanding REMS and Its Importance REMS were established under the Food and Drug Administration…
Regulatory consequences of missed or delayed REMS and PMR milestones
Understanding the Regulatory Consequences of Missed or Delayed REMS and PMR Milestones The pharmaceutical landscape is marked by stringent regulatory requirements, particularly when it comes to post-marketing commitments (PMCs) and Risk Evaluation and Mitigation Strategies (REMS). Both REMS and post-marketing requirements (PMRs) play a crucial role in ensuring drug safety and efficacy, but what are the regulatory consequences if milestones related to these commitments are missed or delayed? This tutorial provides a comprehensive step-by-step overview specifically designed for pharma professionals involved in clinical operations, regulatory affairs, and medical affairs in the United States, United Kingdom, and European Union. 1. Introduction…
KPIs to measure success and burden of REMS and PMR activities
KPIs to Measure Success and Burden of REMS and PMR Activities KPI Measurement for REMS and PMR Activities: A Regulatory Compliance Guide Pharmaceutical companies are increasingly faced with the challenge of demonstrating the effectiveness and burden of Risk Evaluation and Mitigation Strategies (REMS) and Post-Marketing Commitments (PMCs). These programs are critical for ensuring patient safety and therapeutic efficacy, especially when a drug’s risk profile necessitates additional oversight after it has entered the market. A systematic approach to measuring Key Performance Indicators (KPIs) for REMS and PMR activities is essential for regulatory compliance and optimisation. Understanding REMS and PMR: Definitions and…
Third party vendor management for REMS hubs and service providers
Third Party Vendor Management for REMS Hubs and Service Providers Third Party Vendor Management for REMS Hubs and Service Providers In the landscape of pharmaceutical regulation, particularly with regard to post-marketing commitments (PMCs), the management of third-party vendors playing a role in Risk Evaluation and Mitigation Strategies (REMS) is crucial. This guide aims to provide pharmaceutical professionals with a comprehensive step-by-step tutorial on effective third-party vendor management for REMS hubs and service providers, highlighting regulatory expectations from the US FDA. Understanding REMS and Its Importance Risk Evaluation and Mitigation Strategies (REMS) are critical tools used by the FDA to ensure…
Budgeting and resource planning for complex REMS implementation
Budgeting and Resource Planning for Complex REMS Implementation The Risk Evaluation and Mitigation Strategies (REMS) framework established by the U.S. Food and Drug Administration (FDA) plays a critical role in ensuring that the benefits of a drug outweigh its risks. This article serves as a comprehensive tutorial for pharmaceutical professionals involved in the budgeting and resource planning necessary for successful REMS implementation. With a focus on US regulations and comparative insights from the UK and EU, we explore the intricacies of complying with post-marketing commitments (PMCs) and post-marketing requirements (PMRs). Understanding the Basics of REMS REMS are risk management plans…
Quality control steps for case narrative, coding and regulatory fields
Quality Control Steps for Case Narrative, Coding, and Regulatory Fields Pharmacovigilance is a critical aspect of drug safety and efficacy, particularly in ensuring that adverse events are accurately captured, codified, and reported. Through rigorous quality control mechanisms in case processing, MedDRA coding, and safety database compliance, pharmaceutical professionals can facilitate better outcomes in drug safety monitoring. This article serves as a comprehensive tutorial, equipping regulatory affairs, clinical operations, and medical affairs professionals with vital steps to achieve adherence to US FDA regulations and guidelines. Understanding the Importance of Quality Control in Pharmacovigilance Quality control in pharmacovigilance encompasses a systematic approach…
How to design triage, duplicate check and follow up in case processing
How to Design Triage, Duplicate Check and Follow Up in Case Processing Case processing in pharmacovigilance (PV) is a vital aspect of ensuring drug safety post-marketing. Proper management of adverse event reports through structured triage, duplicate checks, and follow-ups forms the backbone of a compliant safety database system. This tutorial serves as a comprehensive step-by-step guide to executing these processes effectively, adhering to regulatory frameworks including FDA regulations and European Union directives. This guide aims to equip pharmaceutical professionals, regulatory affairs, and clinical operations personnel with the necessary insights for enhanced case processing. Step 1: Understanding Case Processing Requirements Case…
Safety database validation and 21 CFR Part 11 requirements for PV systems
Safety Database Validation and 21 CFR Part 11 Requirements for PV Systems Pharmacovigilance (PV) is a critical aspect of healthcare, ensuring the safety of medicinal products in the market. As pharmaceutical companies strive to maintain compliance with regulations, it becomes essential to understand the requirements surrounding case processing, MedDRA coding, and safety database compliance. This article aims to provide a comprehensive, step-by-step tutorial on ensuring safety database validation while aligning with the regulations outlined in 21 CFR Part 11. It will also highlight the importance of global standards, including considerations relevant to UK and EU markets. Understanding 21 CFR Part…
Best practices for MedDRA coding to support signal detection and labelling
Best practices for MedDRA coding to support signal detection and labelling Best practices for MedDRA coding to support signal detection and labelling Medication safety is a paramount concern in the pharmaceutical industry, particularly in the domains of pharmacovigilance and post-market compliance. Central to these efforts is MedDRA (Medical Dictionary for Regulatory Activities) coding, which supports effective case processing in safety databases. This article will provide a step-by-step tutorial on best practices for MedDRA coding, focusing on its relevance for signal detection and labeling. The content is particularly aimed at pharmaceutical professionals involved in clinical operations, regulatory affairs, and medical affairs…
End to end case processing workflows for compliant pharmacovigilance systems
End to End Case Processing Workflows for Compliant Pharmacovigilance Systems End to End Case Processing Workflows for Compliant Pharmacovigilance Systems In the rapidly evolving world of pharmaceuticals, efficient and compliant pharmacovigilance (PV) systems are paramount. This step-by-step tutorial is designed to guide pharma professionals through the essential workflows associated with case processing, MedDRA coding, and safety database compliance. Adhering to regulations from authorities such as the US FDA is critical for successful drug safety monitoring. Understanding Pharmacovigilance and Its Importance Pharmacovigilance refers to the science andactivities related to the detection, assessment, understanding, and prevention of adverse effects or any other…